

The image shows two scientists, a woman and a man, in a laboratory setting. They are both wearing white lab coats with the CSL logo on the chest. The woman is on the left, wearing safety glasses and smiling. The man is on the right, also wearing safety glasses and smiling. They are working at a lab bench with various pieces of equipment, including a large piece of machinery on the right and a rack of pipettes. The background is a modern laboratory with large windows and glass partitions.

CSL

Driven by **Our Promise**

Tax Transparency Report
2023/24

Our Purpose

The people and science of CSL save lives. CSL develops and delivers innovative medicines that help people with serious and life-threatening conditions live full lives and protects the health of communities around the world. CSL Values guide us in creating sustainable value for our stakeholders.

Contents

Introduction from the Interim Chief Financial Officer	2
About CSL	3
CSL at a glance – 30 June 2024	4
CSL's Businesses	4
CSL's Locations as at 30 June 2024	5
CSL's Value Creation Chain	6
CSL's 2030 Strategy	8
Powered by Innovation	10
CSL's Global Research and Development Pipeline	11
Our Approach to Tax Governance and Tax Strategy	12
Summary of CSL's International Related Party Dealings	13
Australia	15
Switzerland	16
Germany	17
United States	18
United Kingdom	19
Our Global Tax Profile	20
Basis of Report Preparation	23

Introduction from the Interim Chief Financial Officer

I am pleased to present CSL's Tax Transparency Report for the year ended 30 June 2024. The report is in keeping with the Australian Voluntary Tax Transparency Code and aims to provide a greater understanding of CSL's tax profile, tax contributions, and the manner in which we govern and manage our tax obligations. The report also provides information on our international tax footprint and our related party dealings, reflecting the global and integrated nature of our business.

Our success as a global biotechnology company is built around key capabilities in early-stage research and collaboration, product development and clinical trials, manufacturing and distribution and sales, marketing and patient support. We specialise in the manufacture and distribution of our life-changing therapies and vaccines. Being able to create value in these ways is a great privilege, but also a responsibility. Good governance is an essential part of this responsibility.

While CSL's roots are proudly Australian, CSL is a truly global organisation, more than 93% of revenues are derived outside Australia. Our specialised global manufacturing operations are based in Australia, Germany, Switzerland, the United Kingdom and the United States. We operate in over 40 countries and serve patients in more than 100 countries, and we welcome the opportunity to explain the global nature of our business in this report.

CSL has a low appetite for tax risk and does not engage in aggressive tax planning. Operating with transparency forms a core part of CSL's tax management philosophy and CSL continues to support efforts to improve tax transparency and fairer economies through confidence in the robustness of country tax regimes.


CSL is subject to different tax regimes in each of the countries we operate in, and we comply with applicable taxation laws in all of the jurisdictions in which we operate, including Pillar Two and Country-by-Country reporting measures (CbC) from the Organisation for Economic Co-Operation and Development (OECD). These measures provide Tax Authorities around the world with details of how we conduct our business and how CSL's international related parties transact with each other.

CSL's tax payment profile aligns with our profit generation profile – we pay taxes in the jurisdictions where we make profits, and the majority of CSL's tax is paid in the countries where we have the most significant operations. This reflects OECD transfer pricing principles of aligning economic return in a country with the value creation occurring in that country.

In the year to 30 June 2024, CSL paid US\$784 million of corporate income taxes globally. In our material jurisdictions, CSL paid various other taxes amounting to US\$170 million, collected and remitted US\$1.2 billion of indirect taxes, as well as claimed and processed US\$1.4 billion of indirect tax credits and employee taxes.

A fair economy is one that is efficient and productive. Delivering sustainable, profitable growth is a fundamental part of CSL's strategy to ensure that all of our stakeholders benefit. In the context of an ever more challenging and complex operating, economic and regulatory environment, CSL remains acutely focused on serving unmet patient needs and adding value to healthcare systems.

A more streamlined and predictable regulatory environment helps companies like CSL bring new therapies to market more quickly and efficiently, and ultimately, improves global health outcomes. CSL encourages governments to reduce unnecessary regulatory burden and introduce policies that foster innovation, enhance competitiveness and drive productivity.



John Levy
Interim Chief Financial Officer

US\$784m

corporate income
taxes paid globally

US\$170m

various other taxes in
material jurisdictions

US\$1.2b

indirect taxes collected
and remitted

US\$1.4b

indirect tax credits and
employee taxes claimed
and processed

About CSL

CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology.

Since CSL's start in 1916, we have been driven by our promise to save lives using the latest technologies. CSL Limited was incorporated in 1991 and listed on the Australian Securities Exchange (ASX) in 1994. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000+ people.

CSL distributed US\$13.5 billion in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions. In addition, we invested US\$1,258 million across the organisation to support future growth.¹

CSL has expanded rapidly through strategic acquisitions of a number of businesses:

2000

Swiss company, ZLB, was acquired in 2000, and Aventis Behring was acquired in 2004, with operations predominantly in the US and Germany.

2015

Novartis' influenza vaccine business was acquired in 2015.

2017

CSL entered the cell and gene therapy field in 2017, and expanded our reach in this therapeutic area through the commercialisation and license agreement with uniQure for HEMGENIX® (etranacogene dezaparvovec), the first FDA-approved gene therapy for adults with haemophilia B.

2020

Vitaeris was acquired in June 2020, expanding our transplant therapeutic area portfolio.

2022

In August 2022, CSL completed the acquisition of Vifor Pharma AG, a global pharmaceutical company listed on the Swiss stock exchange. This acquisition broadens CSL's global reach and capabilities in the areas of iron deficiency, dialysis, nephrology and rare disease.

In December 2022, CSL finalised a global collaboration and license agreement with Arcturus Therapeutics Holdings Inc, which provides CSL with access to Arcturus' late stage self-amplifying mRNA vaccine platform technology.



1. Cash payments made for property, plant and equipment (PPE) and intangibles for the year ended 30 June 2024.

CSL at a glance

30 June 2024

US\$2.64

dividend per share
for 2024

100+

countries that CSL
provides lifesaving
products to patients

US\$14.8b

in annual revenue

US\$5.8b

in R&D investments in the
last five years to advance
CSL's product pipeline

110 million

influenza doses
distributed in FY24

349

plasma collection centres
across China, Europe and
North America

2,500+

R&D employees working
in R&D centres located in
leading biomedical
locations in 10 countries

32,000+

employees worldwide

Operating in

40+

countries around the world

CSL's Businesses



CSL Behring is a global biotherapeutics leader driven by CSL's promise to save lives. Focused on serving patients' needs by using the latest technologies, CSL Behring discovers, develops and delivers innovative therapies for people living with conditions in the transplant, immunology, haematology and cardiovascular therapeutic areas.

CSL Behring uses three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives.

CSL Behring operates CSL Plasma, one of the world's largest plasma collection networks.



As one of the leading influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.


CSL Seqirus operates state-of-the-art production facilities in the United States, the UK and Australia and uses both egg-based and cell-based manufacturing technologies as well as a proprietary adjuvant. It has a broad and differentiated product portfolio and commercial operations in more than 20 countries.




CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. CSL Vifor specialises in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).

CSL's Locations

Global presence as at 30 June 2024



Operating in
40+
countries around
the world



CSL's Value Creation Chain

Key value drivers

CSL's people

More than 32,000 people with diverse skills that drive the Company's purpose and values

Physical assets

Plasma donation centres to collect vital raw material, manufacturing facilities for CSL products, warehouses, research and development facilities and offices for CSL's people

Solutions for unmet needs

Opportunities to improve and protect the quality of life of patients and communities in CSL's therapeutic areas

Business partners

Accessing and sharing intellectual know-how to develop and innovate CSL products


Natural resources

Plasma donations for rare and serious diseases; influenza virus strains for vaccine manufacture; iron sources (including synthetic) for iron-based products; and environmental inputs such as water and energy

Financial resources

Cash, equity and debt for future growth

CSL's value creation cycle



⊕ Read more at investors.csl.com/investors/our-corporate-profile

⊕ Read more at csl.com/we-are-csl/corporate-governance/code-of-responsible-business-practice

CSL's Value Creation Chain

Continued from page 6

	What we do	The value we create
CSL's people	Provide a safe, rewarding and productive workplace for promising futures	Empowering CSL's people through rewarding jobs, career development opportunities and professional training
Physical assets	Driven by safety, quality, reliability, and innovation in our operations	CSL's facilities are critical for the development and manufacture of its life-saving and life protecting products, while providing a safe and productive workplace
Solutions for unmet needs	Powered by research and development to identify new indications for CSL's existing products, and innovative new products for patients and public health	Enhanced scientific knowledge and skills through strong collaborations, leading partnerships and high standards of integrity in performing clinical trials
Business partners	Collaborative partnerships to extend CSL's limits	CSL works with partners allowing the Company to leverage capabilities throughout the value chain and optimise costs. It also creates economic opportunities for CSL's supply partners and the communities they operate in
Natural resources	Responsibly source materials and inputs embedding environmental and social considerations into work practices	Protecting global health and the wellbeing of individuals, families, businesses and communities from life-threatening and/or complications resulting from influenza. Saving and/or improving the quality of life of hundreds and thousands of people with rare and serious diseases.
Financial resources	Sustainable financial growth with a focus on revenue and margins	Delivering consistent, profitable and responsible growth for CSL's investors, which fuels innovation and economic prosperity for multiple stakeholders



Read more at [CSL.com/we-are-csl/our-businesses-and-products](https://www.csl.com/we-are-csl/our-businesses-and-products)

CSL's 2030 Strategy*

CSL operates with a long-term mindset.

Over time, we have served patients with life-saving therapies and effective vaccines. We have achieved consistent top-line growth and strong margins, which helps fuel further growth by allowing us to re-invest in our own businesses.

CSL is committed to the 2030 Strategy which includes Focus in core therapeutic areas, Innovation, Efficiency & Reliable Supply, Sustainable Growth, and Digital Transformation, with CSL people and our patients at the centre. We believe this is the best path, given our capabilities in an increasingly challenging and competitive world. The core elements of the 2030 Strategy are shown to the right.



Read more at [csl.com/we-are-csl/corporate-governance/code-of-responsible-business-practice](https://www.csl.com/we-are-csl/corporate-governance/code-of-responsible-business-practice)

* Taken from CSL's FY2024 Annual Report.

CSL's 2030 Strategy

Continued from page 8

Strategic Pillar

Our approach



Focus

- Immunology
- Haematology
- Nephrology and transplant
- Respiratory
- Cardiovascular and metabolic
- Vaccines

- Delivering groundbreaking innovation in areas of unmet need in CSL's Therapeutic Areas

- Driven to meet the needs of patients by leveraging our scientific and clinical expertise to provide the best possible therapies and vaccines



Innovation

- Products
- Delivery
- Services
- Technology
- Yield

- Disrupting with cutting edge innovation and a portfolio of products to enhance patient care and public health (for more, see the Innovation section)

- Committed to finding innovative approaches to increase yield across core platforms



Efficiency & reliable supply

- Technology
- Operational excellence
- Capital project execution
- Partnerships

- Driving efficiency across the supply chain, from collections through manufacturing and to patients

- Striving to maximise value and deliver milestones with key alliances and partnerships



Sustainable growth

- Plasma protein technology
- Recombinant protein technology
- Cell & gene therapy
- Vaccines technology
- Iron therapy

- Growing the value of key franchises in plasma, vaccines and iron in a sustainable way by driving market access, using real world evidence and medical capabilities

- Continuing to launch key products and indications for CSL's next phase of growth



Digital transformation

- Enterprise Value
- Worker Productivity
- Information Velocity

- Building and leveraging data and partnerships to embrace digital transformation across its business

- Prioritise opportunities to use AI that drive business value while scaling user-friendly tools for broad productivity

Powered by Innovation


THERAPEUTIC AREAS



Immunoglobulins



Transplant & Immunology



Haematology



Cardiovascular & Renal



Vaccines

PLATFORMS

Plasma Protein Technology

Recombinant Protein Technology

Genetic Medicine

Vaccines Technology

Innovation is a critical pillar of CSL's 2030 strategy. It underpins everything we do, from One R&D, to CSL Plasma centers, to CSL's manufacturing sites and enterprise-wide digital architecture.

Innovation in CSL is driven by its R&D organisation with over 2,500 employees located within biotech hubs and precincts in 10 countries around the world that are linked to strong research networks and external collaborations that CSL actively establish and foster. CSL's R&D employees work in R&D centres located in leading biomedical locations, including at the following key jurisdictions:

- Melbourne, Australia
- Marburg, Germany
- Bern and Zurich, Switzerland
- London, UK
- Holly Springs, Kankakee, King of Prussia, Pasadena and Waltham in the US.

A philosophy of global collaboration underpins CSL's presence within those research precincts and provides access to worldwide, leading innovation to advance the discovery and development of pioneering biotherapies to address unmet medical needs in CSL's areas of focus. CSL's world-class R&D organisation continues to advance as a biotechnology leader by delivering transformative science and technologies developed by CSL's own high-calibre scientists and innovative scientific collaborations.

In 2023/24 CSL invested US\$1.4 billion in R&D globally for its three businesses. Looking towards 2030, CSL is dedicated to maintaining a strong innovation pipeline grounded in scientific rigour by focussing on strategic therapeutic areas and leveraging its technical development platforms. CSL defines a "strategic platform" as an area where it has the expertise to manufacture a new therapy or vaccine at every stage in its lifecycle, such as plasma protein technology, recombinant protein technology, genetic medicine, and vaccines technology. These platforms facilitate ongoing innovation in the development of products to address unmet medical needs, prevent infectious disease and help patients lead full lives.

CSL R&D leverages its expertise in CSL's strategic platforms to develop and deliver innovative medicines and vaccines via CSL's three business units – CSL Behring, CSL Seqirus and CSL Vifor. CSL R&D also applies its clinical, safety and regulatory expertise to support CSL Plasma. These efforts address unmet medical needs, help prevent infectious diseases and protect public health, enabling people everywhere to lead full lives and helping CSL grow in the decades ahead.

CSL's strong R&D pipeline includes potential new treatments that use these platforms in alignment with its leading-edge scientific expertise and commercial capabilities across CSL's therapeutic areas: immunoglobulins; transplant and immunology; haematology; cardiovascular and renal; and vaccines.

CSL's R&D portfolio focuses on innovation in novel treatment options, improved products and manufacturing expertise, ensuring CSL's continued growth. In pursuit of these goals, CSL recognises and embraces that we cannot, and should not, do it alone. When collaboration becomes the driving force behind progress in biomedical ecosystems, it brings benefits to various stakeholders including universities, research institutions, pharmaceutical companies and, crucially, patients.

Thus, CSL continues to identify and build strategic collaborations that align with CSL's therapeutic areas of focus and enhance CSL's chances of bringing forward beneficial transformative innovation. Identifying early-stage external innovation opportunities, such as new technologies and assets, is essential to grow and diversify CSL's research portfolio.

CSL's Global Research and Development Pipeline

(As at 22 October 2024)

Phase I	Phase II	Phase III	Registration/Post-Registration		
Anumigilimab Anti-G-CSFR mAb (SCD)	Horizon 2 Ig Yield	HIZENTRA® (SCIg) 20% Liquid (CLL)	HIZENTRA® (SCIg) 20% Liquid	FILSPARI® (Sparsentan) Dual ETA & AT1 antagonist (IgAN)	AUDENZ®/CELLDEMIC® Adjuvanted Cell-based Monovalent Influenza A (H5N1) Vaccine
CSL040 Complement R1 Inhibitor	CSL787 Nebulised Ig	HIZENTRA® (SCIg) 20% Liquid (POTS)	PRIVIGEN® (IVIg) 10% Liquid	KORSUVA®/KAPRUVIA® KOR. agonist (CKD-aP)	FOCLIVIA®/AFLUNOV® Adjuvanted Egg-based Influenza A (H5N1) Vaccine
CSL405 Cell-based Influenza (H2N3) Vaccine	Hemopexin (VOC in SCD)	RiaSTAP® Fibrinogen Concentrate (AFD)	ZEMAIRA®/RESPREEZA® Alpha 1 Antitrypsin	RAYALDEE® Oral ext. release calcifediol (SHPT)	FLUAD® Trivalent* Adjuvanted Egg-based Influenza Vaccine
CSL406 sa-mRNA Influenza (H5N1) Vaccine	Vamifeport Ferroportin inhibitor (HH)	Clazakizumab Anti-IL-6 mAb (ESKD)	HAEGARDA® C1 Inhibitor (HAE)	TAVNEOS® Oral C5a receptor inhibitor (AAV)	FLUCELVAX® Trivalent Cell-based Influenza Vaccine
CSL400 (TIV) sa-mRNA Trivalent Influenza Vaccine	CSL301 Anti-α2AP mAb (sPE)	CSL964 Alpha 1 Antitrypsin (Treatment of aGvHD)	Garadacimab Anti-FXIIa mAb (HAE)	VELPHORO® Sucroferric oxyhydroxide (Serum P control in CKD)	KOSTAIVE® sa-mRNA Vaccine (COVID)
LASN01 Anti-IL-11R mAb (IPF,TED)	CSL525 (SNF472) Calcification inhibitor (CUA-ESKD)	CSL964 Alpha 1 Antitrypsin (Prevention of aGvHD)	AFSTYLA® rFVIII (Haem A)	VELTASSA® Oral potassium binder (HK)	
	Eblasakimab (CSL334) Anti-IL-13R mAb (AD)	FLUAD® Trivalent Efficacy Adjuvanted Egg-based Influenza Vaccine	IDELVION® rFIX-FP (Haem B)		
		CSL403 (aTIVc) Adjuvanted Cell-based Trivalent Influenza Vaccine	HEMGENIX®* (Haem B)		

■ Immunoglobulins
 ■ Haematology
 ■ Cardiovascular & Renal
 ■ Transplant & Immunology
 ■ Vaccines
 ■ Outlicensed Programs
 ■ ** Partnered Projects

* Ongoing Post-Marketing Studies.

Our Approach to Tax Governance and Tax Strategy



CSL's approach to tax governance and tax strategy is guided by our Code of Responsible Business Practice, which sets out CSL's values and principles of conduct. Our decisions in relation to tax are consistently made in accordance with this code. At CSL, we are committed to conducting all aspects of our business in an ethical and transparent way.

CSL has a low appetite for tax risk and seeks to manage its global tax affairs in a manner that maintains the integrity and reputation of CSL at all times.

Tax is considered a core part of CSL's corporate responsibility, with tax governance overseen by the Board. CSL's approach to tax is underpinned by our value of Integrity.

CSL's approach to tax is underpinned by our value of Integrity

CSL's approach to tax is guided by the following principles, which are the basis of our Tax Strategy:



Compliance

CSL is committed to complying at all times with the requirements of the law, and also with CSL's understanding of the intent of the law. Tax positions adopted must be cogent and well grounded. The principles in the OECD Transfer Pricing Guidelines will be adopted when determining the appropriate transfer price for transactions between International Related Parties.



Governance

The Board approves the Tax Policy, and has ultimate responsibility for ensuring there is an effective process to manage tax risk. The CFO is responsible for monitoring the effectiveness of the Tax Risk Management Framework.



Business Structure

CSL will only implement transactions that are aligned with our business activity, have clear commercial objectives, and do not rely on tax for their commercial viability. We will not operate artificial or aggressive tax structures.



Transparency

Publish an annual tax transparency report to explain our tax payments and a reconciliation between tax and financial results.



Relationships

CSL operates with integrity and transparency to maintain open, respectful and co-operative relationships with Tax Authorities. Where appropriate, CSL will seek advance rulings from Revenue Authorities to provide certainty to CSL.

Summary of CSL's International Related Party Dealings

Collaboration is at the heart of CSL's success, and this is reflected in our globally integrated value chain which employs more than 32,000 people and operations in over 40 countries. In order to best serve the needs of our patients, CSL's companies and employees conduct business with each other throughout the entire value chain to drive an integrated enterprise-wide approach and meet the global demand for our lifesaving medicines.

The majority of CSL's related party transactions are between our entities located in Australia, Germany, Switzerland, UK and the US. Approximately 92% of our employees are located in these countries, working across various functions such as manufacturing, R&D and commercial operations.

A significant proportion of CSL's growth has been achieved through global acquisitions, resulting in a broad geographical manufacturing network, and products that are owned by different entities within the CSL Group.

To facilitate the development, manufacture, and sale of our products across a global value chain, the relevant 'product owner' will engage other CSL related entities to carry out certain supply chain functions, such as contract R&D, supply of intermediate product, distribution and, in some cases, components of manufacturing. Innovation in CSL is driven by an integrated R&D organisation with a philosophy of global collaboration.

CSL is also continuing to focus on enterprise-wide consistency and simplification of our organisational structures and processes in global enabling functions such as finance, information & technology, procurement and human resources. These functions support CSL's business segments, and drive further operational efficiencies for the organisation.

Pricing of Intercompany Transactions

In line with our Tax Policy, CSL has a robust transfer pricing policy and transfer pricing guidelines in place that comply with the OECD transfer pricing guidelines.

Transactions between related parties are undertaken as if the transactions were carried out between unrelated parties. This is referred to as 'the arm's length principle' and determines how profits are allocated between countries, which in turn is a component of the amount of tax paid in a country. CSL ensures that transactions in our value chain are priced to reflect the value created, with consistent application of OECD principles and in compliance with our tax obligations. Transfer prices are determined by reference to benchmark data, noting that this is a complex area, the application of which can be subject to differences in interpretation by global Revenue Authorities.

CSL has a bilateral Advanced Pricing Arrangement (APA) with tax authorities on pricing in respect of a portion of our related party dealings. CSL has also submitted a further application for related party dealings not covered by the APA noted above. CSL appreciates the confidence that future focused agreements provide in relation to ensuring compliance with tax laws.

The following activities are conducted between CSL related parties

Research and Development (R&D)

CSL's world-class R&D organisation is an integrated global function operating across our three business segments (CSL Behring, CSL Seqirus and CSL Vifor) and continues to advance as a biotechnology leader by delivering high-quality science and technologies developed by our own high calibre scientists and innovative collaborations. Approximately 10% of global revenue was invested in R&D in 2023/24 across all phases of the R&D lifecycle – including research to discover new molecules, develop clinical candidates, product development and clinical trials. Our R&D pipeline fuels the company's sustainable growth.

The CSL entity that owns a product will be responsible for future R&D in relation to that product and may engage other entities around the CSL Group to conduct contract R&D on its behalf. Contract R&D services result in arm's length charges for the R&D services provided by one CSL company to another.



Summary of CSL's International Related Party Dealings

Licensing of IP

There are limited instances in the group where IP is owned by one entity, and that IP is licensed to another company in the group. Where this occurs, an arm's length royalty is paid to the licensor of the IP.

Plasma Collection and Manufacturing

CSL has specialized and integrated manufacturing sites in Australia, Germany, Switzerland, the UK and the US. CSL's End to End Supply Chain model and our Enterprise Resource Planning system ensures integration across the network, better utilisation of assets, diversification of risks and improvements in supply reliability.

There are a number of possible related party dealings that occur during the plasma collection and manufacturing stage:

- Raw material (i.e. plasma) for production is sourced by the CSL network. For example, plasma sourced in the US is provided to Germany and Switzerland, where the plasma is used to manufacture intermediate or finished goods.

- Intermediate product can be provided by one manufacturing facility to another for further processing. For example, our manufacturing site in the US provides intermediate product, typically a 'paste' to manufacturing operations in Germany, Switzerland and Australia, where it is converted into finished goods.
- Products can be manufactured by one CSL entity on behalf of another, this allows for the efficient utilisation of our global manufacturing network and mitigates supply risk.

The manufacturer is compensated with an arm's length return for the manufacturing services performed.

Sale of Product

CSL's finished goods are mainly sold into local markets through subsidiary distributors. Where the distributor is not the manufacturer, the distributor purchases the finished product at an arm's length price from the product owner. CSL has distribution entities throughout the world.

Financing

CSL has some instances of inter-company loans arising between related parties. Arm's length interest rates are charged in respect of any intercompany loans.

Management and Marketing Fees

A number of management, marketing, finance and administrative functions are performed by certain entities within the group that benefit other CSL entities worldwide. This is more efficient than if each country was to also perform the same function. The entity providing the service charges the recipient entities an arm's length fee.

Note: For the purposes of clarity for Australian tax transparency reporting, CSL's Australian entities engage with its related parties in each of the above categories.

CSL's Material Subsidiaries*

The ultimate controlling entity is CSL Limited, otherwise described as the parent company. The following table lists the Group's material subsidiaries as at 30 June 2024. A full listing of controlled entities is outlined within the Group's **consolidated entity disclosure statement**.

CSL's Material Subsidiaries

Company	Country of Incorporation	%	Company	Country of Incorporation	%
CSL Limited	Australia		CSL Behring Holdings Limited	UK	100
Subsidiaries of CSL Limited:			CSL Finance Plc	UK	100
CSL Innovation Pty Ltd	Australia	100	Seqirus UK Limited	UK	100
CSL Behring (Australia) Pty Ltd	Australia	100	CSL Behring LLC	US	100
CSL Behring (Holdings) Pty Ltd	Australia	100	CSL Plasma Inc	US	100
CSL Finance Pty Ltd	Australia	100	CSLB Holdings Inc	US	100
Seqirus Pty Ltd	Australia	100	Seqirus USA Inc	US	100
CSL Behring GmbH	Germany	100	Seqirus Inc	US	100
CSL Behring AG	Switzerland	100	Controlled entities (not wholly owned) of CSL Limited: ^		
CSL Behring Lengnau AG	Switzerland	100	Vifor Fresenius Medical Care	Switzerland	55
Vifor (International) Ltd	Switzerland	100	Renal Pharma Ltd		
Vifor Pharma Participations Ltd	Switzerland	100			

* Extracted from Note 15 of the 2023/24 CSL Limited Annual Report.

^ Represents a participating entity of a joint venture that is consolidated in the Group's consolidated financial information.

Overview of Activities in Key Jurisdictions

Australia



US\$**973**m

External operating revenue

US\$**9**m

Profit

US\$**13**m

Income tax paid

US\$**40**m

Total tax paid

US\$**425**m

R&D expenditure

3,046

Number of employees



CSL headquarters,
Melbourne, Australia

CSL is headquartered in Melbourne, Australia and listed on the Australian Securities Exchange. CSL has invested approximately A\$2 billion in Australian facilities over the past decade, demonstrating strong support for Australia's biopharma manufacturing capabilities and reinforcing CSL's confidence in the skills and expertise of the Australian workforce.

CSL Behring

CSL Behring's manufacturing site is located in Broadmeadows, Victoria. CSL Behring is the national plasma fractionator for the Australian Government and manufactures a range of life saving plasma-derived therapies for the treatment of the Australian community. The Broadmeadows site houses a Plasma Fractionation Facility which is able to process up to 9.2 million input litres per annum and supports end-to-end manufacturing of plasma-derived therapies. The Australian manufacturing plant provides plasma fractionation services for the region, and also manufactures products for global export.

CSL Seqirus

Seqirus Australia currently manufactures egg-based influenza vaccine and products of national significance at its Parkville facility, including antivenoms and Q fever vaccine. CSL Seqirus is also a leading provider and distributor of in-licensed vaccines and specialty pharmaceuticals in Australia.

Construction of the new A\$800+ million cell culture vaccine production facility in Tullamarine has been ongoing since FY22 which will further enable supply of cell-based influenza vaccines to Australia and the rest of the world. The facility is expected to be operational in 2026 and will also produce various products of national significance that are currently being produced in Parkville.

Research & Development

CSL is a significant contributor to driving innovation and jobs growth in the R&D sector in Australia. Melbourne is an important R&D location for the group, as demonstrated by CSL's significant investment in the new R&D facilities in Melbourne's biomedical precinct. In August 2023, the Prime Minister of Australia, Anthony Albanese, officially opened CSL's new Global Headquarters and Centre for R&D. This facility has purpose-built wet laboratory space and houses more than 850 professionals, which will further enable collaboration with other researchers in the biomedical precinct. CSL also continues to operate in the Bio21 Institute, where the early stage research team has been based for over 10 years.

Much of the R&D activity undertaken is eligible for the Australian government's R&D tax incentive, which was introduced to encourage investment and jobs growth in this sector. The R&D Tax Incentive provides tax offset benefits for eligible R&D expenditure.

CSL Australia owns and funds a significant proportion of new research projects and incurs significant R&D expenditure that contribute to carry forward tax offset balances in Australia. These R&D projects present significant opportunities for future profit generation if successful. Garadacimab for example, is CSL's first-in-class recombinant monoclonal antibody targeting activated Factor XII (FXIIa) as a prospective, long-term prophylactic treatment for patients with Hereditary Angioedema (HAE).

Unfortunately, not all our targeted innovation will pay off. In February 2024, results from one of CSL's largest clinical trials ever undertaken targeted at cardiovascular risk reduction (Phase III AEGIS-II Trial evaluating the efficacy and safety of CSL112) returned disappointing results, with the study not meeting its primary efficacy endpoint. While disappointing, CSL will keep focusing on advancing a robust and diverse innovation pipeline to find yet another way to address the ever-changing challenges facing healthcare around the world.

Dividends

CSL Limited, as the parent entity of the CSL Group, receives dividends from subsidiary entities. Dividends received from wholly owned subsidiaries are not subject to further taxation in Australia. Intra group dividends of US\$1.6 billion received during the year have been excluded in deriving the net profit number.

Overview of Activities in Key Jurisdictions

Switzerland



US\$**1,863**m

External operating revenue

US\$**1,327**m

Profit

US\$**58**m

Income tax paid

US\$**62**m

Total tax paid

US\$**354**m

R&D expenditure

2,522

Number of employees

CSL Behring

CSL's operations in Switzerland primarily manufacture finished products and is the owner of intravenous and subcutaneous immunoglobulin products PRIVIGEN® and HIZENTRA®. Immunoglobulins are used in the management of primary and secondary immunodeficiency diseases, neurology and oncology conditions. The Swiss entities sell the products to Swiss third parties, and sell to the CSL Group distribution entities for on-sale to third parties overseas.

CSL's Swiss manufacturing facilities are based in Bern with state-of-the-art immunoglobulin production capabilities for end-to-end manufacturing of immunoglobulin and plasma based products.

In order to meet patient demand for product, CSL Switzerland's technology is used by other manufacturing entities in the CSL network to manufacture products. CSL's Swiss operations sell intermediate paste that is not required for its own manufacturing operations to other network companies for further manufacturing.

CSL has a strategic partnership with Thermo Fisher Scientific Inc for the long-term lease of the state of the art recombinant manufacturing facility in Lengnau. Thermo Fisher have assumed oversight and operation of the facility in Lengnau in order to manufacture and supply CSL Behring with IDELVION®. IDELVION® is CSL's recombinant factor IX albumin fusion protein (rFIX-FP) which is used to control and prevent bleeding episodes in people with haemophilia B.

CSL Vifor

The acquisition of the Swiss listed group Vifor Pharma in August 2022 has enhanced CSL's product portfolio, complementing existing products and offering a wider range of treatments for conditions such as chronic kidney disease (CKD), iron deficiency and nephrology.

CSL Vifor Switzerland is the owner of products in the Vifor portfolio. CSL Vifor Switzerland sell products to third parties as well as CSL Vifor distribution entities for on sale to third parties overseas. CSL Vifor are headquartered in Switzerland and operates manufacturing facilities in St. Gallen.

A number of the CSL Vifor entities in Switzerland have carry forward tax losses which are utilised to offset taxable profits.



Bern, Switzerland



St. Gallen, Switzerland

Research & Development

Our Swiss operations perform R&D activities such as product development and regulatory affairs, for the local business entity and for other companies in the CSL Group. Our Swiss operations derive income that qualifies for the Swiss patent box regime. The 'patent box' regime provides concessional tax treatment on qualifying profits earned by Swiss entities owning eligible patents.

CSL's Swiss Institute for Translational and Entrepreneurial Medicine – known as sitem-insel – is based on the campus of the University of Bern hospital. CSL conducts research at sitem-insel and enters into meaningful collaborations with scientists from both the academic and start-up arenas. These collaborations support the growth of our research pipeline and cutting edge therapeutics. CSL Vifor has research and development facilities in St Gallen and Zurich.

Overview of Activities in Key Jurisdictions

Germany



US\$**1,058**m

External operating revenue

US\$**408**m

Profit

US\$**205**m

Income tax paid

US\$**208**m

Total tax paid

US\$**86**m

R&D expenditure

4,099

Number of employees



Marburg, Germany

CSL Behring

CSL's German operations own and manufacture plasma-based coagulation products used to manage bleeding in patients with bleeding disorders such as haemophilia, along with critical care products and a broad range of specialty products, such as HAEGARDA®, BERINERT®, Beriplex® and KCentra®.

HAEGARDA® is an injectable medicine used to prevent swelling and/or painful attacks in patients six years of age and older with Hereditary Angioedema (HAE). BERINERT® is a plasma-derived C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal, facial, or laryngeal HAE attacks in both adult and pediatric patients.

BERIPLEX is CSL's human prothrombin complex concentrate, which is used to treat bleeding conditions, and Kcentra® helps restore blood coagulation by replenishing the levels of clotting factors that were depleted by warfarin therapy.

The German entity sells their products to third parties in Germany, and to the CSL Group distribution entities for on sale to third parties overseas.

CSL's German operations purchase and sell plasma and intermediate product to and from other network companies, for use in manufacturing operations. The German business also manufactures product on behalf of other entities in the CSL network.

CSL's new base fractionation facility in Marburg was opened in March 2023 and enables CSL to better meet global demand for its specialty medicines, by leveraging best practice equipment and processes to further improve efficiency.

The Marburg site supports end-to-end manufacturing of both plasma-derived and recombinant therapies, and houses a base fractionation facility which is able to process up to 6.6 million input litres per annum.

CSL Plasma

CSL Plasma's EU headquarters are based in Marburg, with 14 collection centres located across Germany (and four more currently under construction). CSL Plasma Germany collects, purchases and sells source plasma to CSL network companies for further processing into intermediate, semi-finished and finished products. CSL Plasma in Germany also has plasma testing and logistics capabilities.

Sale of Product

Products from all three CSL business segments (CSL Behring, CSL Seqirus and CSL Vifor) are distributed in the German market.

Research & Development

CSL's German R&D team is based at Marburg, and undertake R&D activities across the full spectrum of R&D functions, including research, product and clinical development and global regulatory affairs. The German based R&D team conduct activities in relation to German owned products and provide R&D services to other CSL companies.

Following three years of construction, CSL opened the new M600 centre in September 2022, which is a R&D campus located in Marburg, Germany. This site is home for up to 500 CSL R&D employees, making it CSL's largest R&D hub worldwide and combining all disciplines under one roof.

Overview of Activities in Key Jurisdictions

United States



US\$**6,367**m

External operating revenue

US\$**489**m

Profit

US\$**250**m

Income tax paid

US\$**374**m

Total tax paid

US\$**572**m

R&D expenditure

17,933

Number of employees



Waltham MA, US

CSL Behring

CSL Behring's operational headquarters is located in King of Prussia, Pennsylvania, with manufacturing operations in Kankakee, Illinois. The Kankakee site primarily manufactures intermediate products that are shipped worldwide to the CSL manufacturing network for further manufacture into finished products. Finished products manufactured include albumin, which is used to treat blood volume loss as a result of trauma or surgery and Zemaira, used to treat hereditary emphysema. CSL Behring US also manufactures some products on behalf of other CSL companies where the IP owner has manufacturing capacity constraints.

CSL Plasma

CSL Plasma is one of the largest plasma collection networks in the world and is headquartered in Boca Raton, Florida. CSL Plasma ensures that there is efficient sourcing of plasma for use in the CSL Behring business to manufacture plasma protein therapies. There are now in excess of 320 plasma collection centres in the US.

Innovation with respect to plasma collection is of increasing importance and CSL Plasma has developed some of the most efficient processes and systems in the plasma industry.

CSL Seqirus

CSL Seqirus has a state-of-the-art facility at Holly Springs, North Carolina, where cell-based technology is used to produce FLUCELVAX® influenza vaccine. With testing now based in Holly Springs, CSL Seqirus has been able to simplify and streamline the testing process to release FLUCELVAX® influenza vaccine into the US each season. With fill and finish capacity expansion projects in Holly Springs completed in recent years, CSL Seqirus is able to streamline production process more efficiently, and better meet patient and public health needs. This site allows for increased fill and finish manufacturing capacity for both cell-based and adjuvanted influenza vaccines, and retains capacity for rapid ramp up of pandemic vaccine production. This capacity ensures that CSL Seqirus is able to support US health authorities on pandemic preparedness.

Sale of Product

The US market is a key market for CSL products, and CSL US entities distribute products from all three CSL product segments (CSL Behring, CSL Seqirus and CSL Vifor) in the US market.

Research & Development

The US based R&D team has a strong focus on clinical development and gene therapy. During the year, the first patients were dosed with HEMGENIX®, the groundbreaking gene therapy for haemophilia B patients that was commercialised and licensed by CSL from UniQure.

A significant milestone for CSL Seqirus' external partnership with Arcturus Therapeutics was achieved through the approval of KOSTAIVE® in Japan, which is the world's first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine for adults 18 years and older. The collaboration agreement with Arcturus Therapeutics remains an important partnership that will continue to drive the development of new vaccines and therapeutics.

CSL's state-of-the art R&D centre in Waltham, Massachusetts, continues to support CSL's growing R&D portfolio, including the next-generation of mRNA vaccine technology, for seasonal and pandemic influenza vaccines.

CSL claims R&D and Orphan Drug credits for qualifying R&D work performed in the US.

Overview of Activities in Key Jurisdictions

United Kingdom



US\$**795**m

External operating revenue

US\$**754**m

Profit

US\$**184**m

Income tax paid

US\$**196**m

Total tax paid

US\$**19**m

R&D expenditure

1,085

Number of employees



Liverpool, UK

CSL Behring

CSL Behring UK is a distributor of CSL products to third parties in the UK market. It does not have any manufacturing facilities in the UK, nor does it own any product technology.

CSL Seqirus

CSL Seqirus was newly formed in 2015 when CSL acquired the influenza vaccine business of Novartis.

CSL's principal business in the UK is CSL Seqirus. CSL Seqirus has corporate hubs in Maidenhead, Berkshire and Liverpool that provide various central headquarter and shared services to CSL entities around the world.

CSL Seqirus UK own and manufacture the differentiated product FLUAD®, which is an adjuvanted product for the elderly market.

CSL Seqirus' Liverpool site is the largest vaccine manufacturing facility in the UK, and one of the largest in Europe. This site is able to produce over 50m doses of seasonal influenza vaccine each year, with the ability to increase production to 200m doses in the event of an influenza pandemic.

The Liverpool site manufactures and formulates bulk material for a range of influenza vaccines, and also produces MF59®, which is CSL Seqirus' novel immune-enhancing adjuvant used in the production of FLUAD®.

With high-speed fill and finish capabilities at the Liverpool site, CSL Seqirus is able to provide start-to-finish onshore manufacturing in the UK. CSL Seqirus is also an important partner to various governments globally on pandemic preparedness, including the UK, Canada, Switzerland and the EU. These governments reserve pandemic vaccine doses from our manufacturing facilities in the UK to protect the population in the event of an influenza pandemic. CSL Seqirus also supplies pre-pandemic vaccine stockpiles that could be deployed to first responders upon a declaration of an influenza pandemic.

Sale of Product

Products from all three CSL business segments (CSL Behring, CSL Seqirus and CSL Vifor) are distributed in the UK market.

Research & Development

There are R&D facilities based at Liverpool. The focus of the UK R&D team is on the vaccines therapeutic area.

Developing new and better vaccines across all age groups in expanded markets is a strategic priority for CSL Seqirus. CSL Seqirus is focused on developing differentiated vaccines protecting against respiratory viruses, influenza and COVID-19 utilising innovative technologies, including further advancing our MF59® adjuvant. Through these technologies, CSL Seqirus aims to enhance the immune response of those particularly vulnerable to influenza and COVID-19, such as children and older adults. A key investigational product in the CSL Seqirus R&D portfolio includes a higher dose adjuvanted cell-based influenza vaccine (aTIVc) which combines FLUCELVAX® antigen with MF59® adjuvant. Adjuvants help to improve immune response and reduce the amount of antigen needed for each vaccine, enabling more doses to be manufactured more rapidly.

Our Global Tax Profile

Calculation of Tax Expense

The Global Effective Tax Rate represents the tax expense calculated in accordance with Australian Accounting Standards, and is included in CSL's annual report. This is calculated by dividing the income tax expense by the profit before tax. It reflects the amount of tax that arises on the year's activities.

Consolidated Entity

Values Per CSL Limited 2024 Annual Report

	2024 US\$m
Profit before income tax expense	3,375
Income tax expense	(661)
Net profit for the period	2,714
Attributable to:	
– Shareholders of CSL Limited	2,642
– Non-controlling interests	72
Global Effective Tax Rate	19.6%

Australian Effective Tax Rate

	2024 US\$m
Profit before income tax expense	1,613
Less Exempt Dividend ¹	(1,604)
Net profit (after adjustment for tax exempt dividend)	9
Income Tax Calculated at 30%	3
Research and development incentives	(7)
Under provision in prior year	8
Other non-deductible amounts ²	5
Income Tax Expense	9

1. Under Division 768A of the *Income Tax Assessment Act 1997*, foreign dividends received from subsidiaries are not subject to Australian income tax.
2. This includes expenses such as non-assessable/non-deductible foreign exchange movements and share based payment expenses.

Our Global Tax Profile

Reconciliation of Accounting Profit to Tax Expense

The effective tax rate differs from the statutory tax rate of 30% due to differences in tax rates in the countries in which we operate, incentives such as R&D or any other country specific allowances and disallowance or limitation of certain deductions in some countries.

Consolidated Entity

	2024 US\$m
Profit before income tax	3,375
Income tax calculated at 30%	1,013
Effects of different rates of tax on overseas income ¹	(387)
Research and development incentives ²	(67)
Under provision in prior year	20
Revaluation of deferred tax balances	(3)
Other non-deductible amounts ³	85
Income tax expense	661

1. This arises due to the global nature of CSL's business. CSL pays tax in the jurisdiction where the income is earned. Some of the jurisdictions we operate in, such as the US, the UK and Switzerland have lower corporate income tax rates than Australia.
2. Governments around the world offer tax incentives to companies that spend money on qualifying research and development activity. This is in recognition of the value and importance of such expenditure. CSL claims tax incentives as a result of R&D activities in Switzerland, Australia and the US.
3. This includes non-assessable/non-deductible amounts such as foreign exchange movements and share based payment expenses.

Calculation of Effective Cash Tax Rate

The Effective Cash Tax Rate represents the tax rate based on total income tax paid to tax authorities during the year. This will always differ from the Effective Tax Rate for the period calculated for accounting purposes. This is due to a variety of factors, such as, cash tax paid in the year may relate to the profits from prior years or determined by reference to fixed instalment rates set by tax authorities. In some key jurisdictions, there may therefore be a significant time lag with respect to tax payments for a particular year. There are also differences in accounting and tax depreciation rates that impact the timing of tax payments, and other tax and accounting timing differences.

Consolidated Entity

	2024 US\$m
Profit before income tax expense	3,375
Income taxes paid	784
Global Consolidated Entity Cash Tax Rate	23.2%

Reconciliation of Tax Expense to Income Tax Payable in respect of Current Year Profits

	2024 US\$m
Tax Expense on profit before tax	661
Total net deferred tax movements affecting tax payable	(57)
Amounts charged to other comprehensive income	16
Amounts credited to equity	–
Income Tax Payable in Respect of Current Year Profits	620

Our Global Tax Profile

Taxes Paid

Country of Operation	Corporate Income Tax Paid US\$m	Employee Taxes Paid US\$m	Other US\$m	Total Taxes Collected US\$m
Australia	13	25	2	40
Switzerland	58	–	4	62
Germany	205	–	3	208
US	250	97	27	374
UK	184	12		196
RoW ¹	74	–	–	74
Total	784	134	36	954

1. For materiality reasons, only corporate income tax has been disclosed for Rest of World (RoW).

Other Taxes Collected and Remitted

Country of Operation	GST/VAT Collected US\$m	GST/VAT Paid but reclaimed US\$m	Employee Taxes Remitted US\$m	Other US\$m	Total Taxes Collected US\$m
Australia	83	(66)	94	–	111
Switzerland	220	(529)	13	–	(296)
Germany	186	(659)	75	–	(398)
US	–	–	219	55	274
UK	223	(163)	31	–	91
Total	712	(1,417)	432	55	(218)

Basis of Report Preparation

The purpose of this report is to provide an overview of the tax contribution made by CSL and provide further information in relation to CSL's tax governance process and tax profile.

The Australian component of the report, has been prepared in line with the Voluntary Tax Transparency Code. Publication of our approach to tax strategy and tax governance is regarded as satisfying Paragraph 16(2), Schedule 19, *Finance Act 2016* (UK).

Financial data disclosed in this report includes amounts attributable to non-controlling interests. Non-controlling interests in the financial results and equity of subsidiaries are shown separately in CSL's consolidated statement of comprehensive income. Please refer to CSL's 2024 [Annual Report](#) Notes to the Financial Statements for further detail on the treatment of Non-Controlling Interests.

Currency

Unless specifically noted otherwise, all data has been disclosed in US dollars.

Income Tax payments have been translated at the exchange rate at date of payment. The balance of tax payments have been translated at the average exchange rate for the year.

External Operating Revenue

This represents external revenue earned by CSL entities operating in each respective jurisdiction, including sales to third parties as well as any other third-party operating revenue. It does not include revenue from sales by the product owner to the group distribution companies.

R&D Expenditure

This represents the expenditure incurred by CSL entities in each respective country and does not include any impairments otherwise accounted for through R&D Expense for purposes of the annual report.

Income Tax Paid

Income tax paid is calculated as the cash income tax paid in the year 1 July 2023–30 June 2024. It is the amount of income tax paid by the CSL entities in that country. It includes both payments made to the local Revenue Authority, and also any withholding taxes paid to foreign governments in respect of income earned by the relevant CSL entity.

Number of Employees

In relation to individual countries, this is based on amount of FTE's and does not include contingent workers. Total global employees is based on employee headcount numbers, including part time employees (as per the annual report).

Other Taxes

This includes items such as property taxes, pharmaceutical taxes, sales and use tax, carbon taxes etc.

Profit

Profit is disclosed on an aggregated basis across all CSL business segments for legal entities whose tax residency is in that country. The profit disclosed is based on the local statutory profit before tax, excluding intercompany dividends.



